Potential Therapeutic Opportunities of TYK2 Therapy Beyond Psoriasis and Identifying the Ideal Patient

This episode, titled ‘Potential Therapeutic Opportunities of TYK2 Therapy Beyond Psoriasis and Identifying the Ideal Patient,’ features panelists Dr. Tina Bhutani-Jacques and Dr. Mark Lebwohl as they examine the systemic impact of psoriasis treatments on patient longevity and comorbidities. Dr. Lebwohl highlights compelling registry data showing that older TNF blockers significantly reduced heart attacks and extended life expectancy by lowering systemic inflammation. He expresses optimism that TYK2 inhibitors will eventually demonstrate similar protective benefits for the heart and joints as more long-term data becomes available. The discussion also touches on the potential for TYK2 inhibitors to be approved for other inflammatory conditions, noting promising off-label results and ongoing studies in lupus, alopecia areata, lichen planus, and psoriatic arthritis.

The experts then pivot to defining the "perfect patient" for this drug class, emphasizing the importance of patient lifestyle and preferences. Dr. Lebwohl identifies pediatric populations and adults with trypanophobia, or a fear of needles, as primary candidates for oral therapy. He shares a clinical anecdote about an Army Ranger candidate to illustrate how the lack of refrigeration requirements makes TYK2 inhibitors superior for patients in austere environments or those who travel frequently. Dr. Bhutani-Jacques adds that many of her patients in the Bay Area prefer the convenience of a pill to avoid the logistical hurdles of traveling with injectable biologics and cooling equipment. The conversation concludes by noting that the reduced stigma of oral medication often makes it a more approachable first-line systemic choice for younger patients who view daily pills as a more routine part of their wellness than injections.

In the next episode, ‘Patient Preferences and Shared Decision-Making in Psoriasis Care’, panelists will walk through the clinical consultation process for initiating systemic therapy. The experts discuss how high-impact areas, patient perception of severity, and specific comorbidities like multiple sclerosis or Crohn's disease dictate the selection of oral versus injectable treatments.